5 Key Takeaways
-
1
Topical NSAIDs may provide modest visual benefits as adjunctive therapy for diabetic macular edema (DME), according to a systematic review.
-
2
The review analyzed six studies involving 446 patients and 892 eyes, focusing on the effects of NSAIDs alongside anti-VEGF therapy.
-
3
Pooled analysis showed a statistically significant improvement in best-corrected visual acuity with NSAID therapy, but clinical relevance is uncertain.
-
4
Anatomical outcomes, including central macular thickness and macular volume, did not show statistically significant benefits from NSAID treatment.
-
5
The authors call for further exploration and larger studies to clarify the long-term efficacy and safety of topical NSAIDs in DME management.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
